Arcellx, Inc. (ACLX)
- Previous Close
52.00 - Open
52.25 - Bid 54.41 x 100
- Ask 54.52 x 100
- Day's Range
52.25 - 55.94 - 52 Week Range
30.74 - 75.10 - Volume
385,613 - Avg. Volume
464,462 - Market Cap (intraday)
2.901B - Beta (5Y Monthly) 0.02
- PE Ratio (TTM)
-- - EPS (TTM)
-1.47 - Earnings Date --
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
80.31
Arcellx, Inc., together with its subsidiary, engages in the development of various immunotherapies for patients with cancer and other incurable diseases in the United States. The company's lead ddCAR product candidate is anitocabtagene autoleucel, which is in phase 2 clinical trial for the treatment of patients with relapsed or refractory multiple myeloma (rrMM). It also develops ACLX-001, a product candidate in Phase 1 clinical trials targeting BCMA to treat rrMM; and ACLX-002, which is in Phase 1 clinical trials that targets CD123 for treating relapsed or refractory acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS). In addition, the company's preclinical product includes ACLX-003 for the treatment of AML and MDS. Further, it focuses on the development of product candidates for solid tumor programs. It has a strategic alliance with Kite Pharma, Inc. to co-develop and co-commercialize anitocabtagene autoleucel. The company was formerly known as Encarta Therapeutics, Inc. and changed its name to Arcellx, Inc. in January 2016. Arcellx, Inc. was incorporated in 2014 and is headquartered in Redwood City, California.
www.arcellx.comRecent News: ACLX
Performance Overview: ACLX
Trailing total returns as of 4/23/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: ACLX
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: ACLX
Valuation Measures
Market Cap
2.77B
Enterprise Value
2.17B
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
22.65
Price/Book (mrq)
5.71
Enterprise Value/Revenue
19.64
Enterprise Value/EBITDA
-33.78
Financial Highlights
Profitability and Income Statement
Profit Margin
-64.08%
Return on Assets (ttm)
-9.86%
Return on Equity (ttm)
-20.48%
Revenue (ttm)
110.32M
Net Income Avi to Common (ttm)
-70.69M
Diluted EPS (ttm)
-1.47
Balance Sheet and Cash Flow
Total Cash (mrq)
702.02M
Total Debt/Equity (mrq)
20.11%
Levered Free Cash Flow (ttm)
12.23M
Research Analysis: ACLX
Company Insights: ACLX
Fair Value
Dividend Score
Hiring Score
Insider Sentiment Score
Research Reports: ACLX
Daily – Vickers Top Buyers & Sellers for 01/09/2024
The Vickers Top Buyers & Sellers is a daily report that identifies the five companies the largest insider purchase transactions based on the dollar value of the transactions as well as the five companies the largest insider sales transactions based on the dollar value of the transactions.
Daily – Vickers Top Buyers & Sellers for 06/24/2022
The Vickers Top Buyers & Sellers is a daily report that identifies the five companies the largest insider purchase transactions based on the dollar value of the transactions as well as the five companies the largest insider sales transactions based on the dollar value of the transactions.
Daily – Vickers Top Buyers & Sellers for 02/11/2022
The Vickers Top Buyers & Sellers is a daily report that identifies the five companies the largest insider purchase transactions based on the dollar value of the transactions as well as the five companies the largest insider sales transactions based on the dollar value of the transactions.